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Abstract
Background: Smith-Magenis syndrome is a complex neurodevelopmental disorder that includes intellectual
deficiency, speech delay, behavioral disturbance and typical sleep disorders. Ninety percent of the cases are due to
a 17p11.2 deletion encompassing the RAI1 gene; other cases are linked to mutations of the same gene. Behavioral
disorders often include outbursts, attention deficit/hyperactivity disorders, self-injury with onychotillomania and
polyembolokoilamania (insertion of objects into body orifices), etc. Interestingly, the stronger the speech delay and
sleep disorders, the more severe the behavioral issues. Sleep disturbances associate excessive daytime sleepiness
with nighttime agitation. They are underpinned by an inversion of the melatonin secretion cycle. However, the
combined intake of beta-blockers in the morning and melatonin in the evening may radically alleviate the circadian
rhythm problems.
Discussion: Once sleep disorders are treated, the next challenge is finding an effective treatment for the remaining
behavioral problems. Unfortunately, there is a lack of objective guidelines. A comprehensive evaluation of such
disorders should include sleep disorders, potential causes of pain, neurocognitive level and environment (i.e. family
and school). In any case, efforts should focus on improving communication skills, identifying and treating attention
deficit/hyperactivity, aggressiveness and anxiety.
Summary: Treatment of Smith-Magenis syndrome is complex and requires a multidisciplinary team including,
among others, geneticists, psychiatrists, neuropediatricians/neurologists, somnologists, developmental and
behavioral pediatricians, and speech and language therapists.
Background
The treatment of genetic disorders associated with neu-
robehavioral phenotype is a major yet complex problem.
Smith-Magenis syndrome (SMS) is one in many exam-
ples of this complexity. SMS is linked to a microdeletion
of chromosome 17 in 90 % of the cases, and entails
major behavioral disorders that jeopardize the social
outcomes of the patients [1–4]. Its prevalence is esti-
mated at 1 in 25,000, although this data may be an
underestimation [5].
SMS is usually caused by a deletion of about 3.5 Mb
on chromosome 17p11.2, and does not result from
parental imprinting. The critical region includes the
RAI1 (Retinoic Acid Induced 1) gene and is less than
650 Kb in size [1–4, 6, 7]. Other genes potentially in-
volved in the phenotype include: PMP22, which is linked
to certain hereditary neuropathies of the Charcot Marie
Tooth type (CMT) or hereditary neuropathy with liability
to pressure palsy (HNPP); TNFRSF13B, which may
cause immunodeficiency related to IgA deficiency;
and MYO15A, which may cause hypoacousia [8–10].
These genes may account for the variability and severity
of the phenotype, whereas the core symptoms seem to be
linked to the haploinsufficiency of the RAI1 gene [8, 11].
In general, the 17p11.2 deletion results from chromo-
some recombination errors during meiosis (crossing-over)
favored by the repetition of certain genome sequences
(LCR or low copy repeat) via a non-allelic homologous
recombination mechanism (NAHR) [12]. These unequal
meiotic recombinations are responsible for 70 % of SMS
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deletions [13]. LCR also favors the occurrence of recipro-
cal duplications, although these are far less often observed
than deletions. Duplications in the 17p11.2 region lead to
a different clinical picture, known as the Potocki-Lupski
Syndrome (PTLS-OMIM 610883), which may be accom-
panied by autistic-spectrum disorders with hyperactivity,
intellectual deficiencies, and congenital malformations.
In 10 % of the cases, the SMS phenotype results from
a point mutation of RAI1 in the heterozygous state. This
gene's loss of function causes RAI1 haploinsufficiency,
which in turn results in a phenotype comparable to that
of SMS by deletion. The RAI1 gene is mainly expressed
in brain tissue [14]. SMS diagnosis is established by
examining a simple peripheral blood sample using fluor-
escence in situ hybridization (FISH) or comparative gen-
omic hybridization (CGH array or ACPA), which is
more costly than FISH but may enable the detection of
an atypical deletion [4, 15]. If test results are negative
and symptoms seem to point to SMS, a molecular biol-
ogy study of the RAI1 gene should be undertaken. Once
the genetic anomaly (deletion or mutation) is identified
in a proband, both parents should be tested to confirm a
de novo event [15].
SMS involves distinctive facial dysmorphia (Fig. 1).
Children with SMS often have light-colored hair, bulging
forehead, moderate hypoplasia of the middle part of the
face and nasal bridge, hypertelorism, oblique outer and
upper palpebral fissures, and synophrys. Micrognathia —
readily observed during the first years of life — reverses
over time, tending towards prognathism characterized
by a wide, square-shaped face (Fig. 1). It may be associated
with dental anomalies such as tooth agenesis (especially
premolar teeth), and/or taurodontism. The child should
be tested for ogival palate, short velum, and velopharyn-
geal insufficiency, especially before a general anesthetic is
administered. Other common ear-nose-throat conditions
include recurring ear infections, sometimes involving
complications such as cholesteatoma, varying degrees of
hypoacousia in 60 % of the cases (one third of which lead
to perceptive deafness, two thirds to conduction deafness),
hoarse voice, and vocal-cord nodes [7, 6–18].
About two thirds of young patients are of short
stature. The limbs are short, with brachydactyly (Fig. 1).
Some cases also show limited elbow-extension span,
clinodactyly of the fifth finger, syndactyly of the second
and third toes, persistence of fetal pads, and polydactyly.
Scoliosis is frequent and should be systematically
screened via clinical examination and spinal cord X-rays.
Android obesity often appears in adolescence [2, 19–21].
Regarding the cardiovascular system, congenital heart
disease has been reported for 30 % of the subjects,
including interventricular or interatrial communication;
tricuspid, mitral, pulmonary, or aortic stenosis; mitral
valve insufficiency and/or prolapse; Fallot's tetralogy;
and anomalous pulmonary venous return. Abdominal
ultrasound may reveal spleen malformations but also
developmental abnormalities in the kidneys and urinary
system (unilateral or bilateral renal hypodysplasia, renal
ectopy and agenesis, ureter duplicity, hydronephrosis,
and megaureter) [6, 22]. From an ophthalmological
point of view, iris anomalies (heterochromia or hamar-
tomas), strabismus, and microcornea have been reported.
Fig. 1 Typical SMS phenotype with ‘tented’ upper lip and depressed nasal bridge a, b, c, d, brachydactyly a, b. Young adults SMS often present
with synophris (d, e) and prognatism d. Wounds from skin picking can be seen at any age d
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Refraction abnormalities are often found and frequently
linked to hypermetropia. Retinal detachment has been
noted, often trauma-related [23, 24]. The phenotype may
vary among subjects presenting identical deletions or mu-
tations, and even between monozygotic twins with SMS.
This shows the absence of a simple correlation between
genotype and phenotype [25, 26]. Hypothyroidism and
hypercholesterolemia may be present, and these para-
meters should be tested regularly. Similarly, deficiencies in
immunoglobulins A, E, and/or G may exist [20, 27].
In addition to the spectrum of physical differences
there are also neuropsychological features of speech and
language delay, sleep disruption, and behavioral disorders
which need a comprehensive approach. With appropriate
treatment, sleep can return to a normal cycle and behav-
ioral disorders can be alleviated, thereby improving the
well-being of the patients. Unfortunately, residual mal-
adaptive behavior often persists despite the treatment of
sleep disturbances, but there is a lack of objective guide-
lines. We propose below a comprehensive evaluation of
behavioral disorders from symptoms to the patient’s
environment. We suggest that the effective treatment
of behavioral disorders in SMS is not limited to psycho-
tropic drugs and should take into account the different
steps of the evaluation.
Discussion
Neurological and developmental disorders in SMS
Sleep-wake rhythm disturbances
In the initial descriptions of SMS, the emphasis was
mainly on maladaptive behavior and hyperactivity; sleep
disorders were seldom mentioned [1, 2, 28]. One of the
first studies focusing on sleep disturbances reported that
62 % of SMS persons presented with sleep disorders: dif-
ficulty falling asleep, problems staying asleep and frequent
awakenings at night [6]. A total absence of paradoxical
sleep (i.e. REM sleep) was sometimes observed [28]. Since
then, several studies have explored the sleep patterns of
SMS persons and confirmed previous data. They also
introduced the notion of abnormal chronology of the
light–dark cycle, which includes falling asleep and waking
up early, and the need for several daytime naps [20, 29–31].
Sleep disorders in neurodevelopmental disorders are
usually multi-factorial and not well understood. Inte-
restingly, de Leersnyder and Potocki found a general
perturbation of the sleep-wake rhythm in SMS, with
inverted secretion of melatonin [30, 31]. Melatonin is the
main hormone produced by the pineal gland from 5-
hydroxytryptamine (5-HT). Normally, peak secretion by
the pineal gland occurs in the middle of the night. It has
been shown, dosing plasma melatonin and urinary meta-
bolites that almost all SMS patients had a phase shift of
their circadian rhythm of melatonin [30, 31]. Time at
onset of melatonin secretion was around 6 AM and peak
time was around 12 PM with a melatonin offset around
8 PM [30]. This observation led to an effective treatment
of SMS disruptive sleep disorder that is detailed below.
The synthesis of the melatonin is triggered by luminosity
variations, i.e., it is inhibited by light. This light-driven
system starts at the retina and then follows the retinohy-
pothalamic tract to reach the suprachiasmatic nuclei of
the hypothalamus. These nuclei are the seat of the main
biological clock of mammals and are responsible for
generating the organism's circadian rhythms. Several clock
genes have been described. They control all circadian
rhythms driven by environmental stimuli [32]. The ex-
pression of these genes oscillates at a circadian rhythm of
approximately 24 h [32]. In SMS, there is only residual
secretion of melatonin at night and an abnormal secretion
peak around noon [30, 31]. We can assume, then, that a
dysfunctional clock gene accounts for the sleep-wake
circadian rhythm disorders in persons with SMS.
Recently, point mutations of the RAI1 gene have been
identified in persons presenting the clinical features of
SMS with inversion of the melatonin secretion rhythm
[33, 34]. These findings clearly stress the role of RAI1 in
SMS sleep disorders. Nevertheless, we know little about
the mechanisms that account for the inverted circadian
rhythm of melatonin secretion observed in SMS. In par-
ticular, the precise role of the RAI1 in modulating light
effects on sleep-wake rhythm remains unanswered.
The SMS sleep disturbance is likely multifactorial and
inversion of melatonin secretion, clock genes disturbance,
phase delay, and behavioral insomnia may contribute to
sleep disturbance.
Neurological disorders
An isolated decrease in active fetal movements is found
in 50 % of SMS cases [35]. During the neonatal period,
hypotonia and difficulty breast-feeding are often ob-
served. These children are usually described by their
parents as being very calm and sleeping a lot. Compared
to other children, they seem to make fewer spontaneous
movements and frequently show hypotonia, which may
contribute to worsen their motor delay [36]. Their walk
may be somewhat unstable but they do not present with
true ataxia. SMS subjects seem to show a certain degree
of insensitivity to pain, which may favor self-mutilation
[37]. Concurrently, hyporeflexia is frequent but generally
not accompanied by reduced motor or sensory conduc-
tion velocity. Certain persons with a large deletion that
includes the PMP22 gene may nevertheless present with
HNPP [20, 35]. Some patients (10-30 %) develop epi-
leptic seizures or asymptomatic EEG anomalies. The sei-
zures vary in terms of age of onset, signs and symptoms,
and severity [38, 39]. Brain imaging may reveal ventricular
or citerna magna enlargement, frontal lobe calcification,
partial cerebellar agenesis, and ‘molar tooth sign’ [38, 39].
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One SMS subject with Moyamoya disease has also been
described [40]. In addition, the volume of the insulo-
lenticular gray matter may be reduced bilaterally in
persons with SMS [37].
Neurocognitive disorders
Virtually all SMS children show a more-or-less pro-
nounced speech delay, with potentially substantial lag
(until age 7) [20]. Oral expression is often difficult,
although comprehension skills are better. This discre-
pancy probably exacerbates behavioral disorders and
seems to be quite typical of the syndrome. Developing
the different modalities of language is thus a treatment
priority.
Studies on the specific cognitive features of SMS per-
sons are scarce. It seems that most patients show mod-
erate intellectual deficiency, with an IQ between 40 and
54 [41, 42]. However, in Osório et al.'s (2012) study on a
group of nine children, two had only slight intellectual
deficiency and one, whose IQ was at the low end of the
general population mean, did not fall into the deficient
category at all [43]. SMS subjects' intelligence thus
covers a wide range of levels [41–43], and their difficul-
ties seem to increase with the extent of the deletion [44].
In our experience, the gap between SMS children and
other children (especially regarding speech delay) often
widens starting at the age of 3, when more specific cog-
nitive disorders set in. However, hyperactivity and atten-
tion disorders worsen the child's problems at school,
although long-term memory and perceptual abilities are
relatively well preserved. By contrast, there is often a
more pronounced deficit in short-term memory, sequen-
tial information processing, and visuomotor, attentional
and executive abilities. There is apparently no premature
age-related cognitive decline in this syndrome [43].
These findings confirm the importance of proposing
individualized neuropsychological assessments, and sug-
gest that the capacities of these patients may be under-
estimated. What's more, the exact impact of therapy
involving early stimulation of neurocognitive functions
has not been documented yet. Their difficulty fitting in
socially is not linked solely to the cognitive phenotype.
Behavioral and sleep disorders also have a deleterious
impact on the quality of life of the patients, their family,
and all the people who support them.
Behavioral disorders
Poor social integration in SMS adults is driven by intel-
lectual deficiency but also by persistent chronic behavioral
disturbance. Thus, an appropriate strategy should be
started early in childhood and should integrate the diffe-
rent behavioral modalities (Fig. 2).
Context of behavioral disorders
In our experience, behavioral disorders often appear
with school or group socialization. They often come in
the form of self-aggressive acts like biting, head banging,
and picking at wounds, which then become chronic. In
our experience, behavioral symptoms are variable in
terms of severity: from mild phenotype (head banging
and finger biting) to severe injuries (recurrent insertion
of pointed objects in soft tissues, third-degree burns,
severe aggression of close relatives …). Stereotypies are
common, especially self-hugging and the tendency to
keep one's hands in one's mouth which is probably the
most specific in SMS and is usually accompanied by
hand and fingers biting. Other less common stereotypies
include licking the index finger and mechanically turning
the pages of a book (“lick and flip”), body rocking, gritting
one's teeth, etc. [6, 45, 46]. During this early period, SMS
children frequently have temper tantrums and show
impulsiveness, clastic behavior, and abrupt changes in
attitude. Change-related anxiety is great, and their
ability to adapt to the surrounding environment is
limited [45, 46].
An important point is that among all the behavior dis-
orders encountered in SMS, aggressive behaviors seem
almost constant [47–50]. For example in a cohort of 32
SMS, the prevalence data was of 96.9 % for self-injurious
behaviors and 87.5 % for physical aggression. This ap-
pears to be a specificity of the SMS, with significantly
higher rates of aggression and destructive behaviors in
SMS people in comparison to patients with intellectual
deficiency of mixed origin [50]. Therefore aggression
and destruction seem to constitute a classical phenotype
in SMS. Indeed, other neurodevelopmental disorders,
such as Rett or X fragile syndromes, inconstantly exhibit
aggressiveness. Among self-injurious behaviors, fingers
and hand biting are very evocative of SMS, especially in
a child with development delay and sleep disorders.
Aggressiveness directed toward others can also be seen.
SMS children often seek for adult attention and seem to
have low interest in other children [45, 51]. Aggression
toward other, especially directed to close relatives, can be
either verbal or physical. In our experience, behavioral
disturbances are not always impulsive and can even be
planned, which is disconcerting for the entourage and
may be another specificity of this syndrome. Indeed, lack
of expressive language, as observed in other neurodeve-
lopmental disorders, is an aggravating factor. But it is not
causal: impulsivity, aggression and hyperactivity may often
increase after a few years at school despite the improve-
ment of communication.
SMS patients may fulfill DSM-5 criteria for specific
diagnoses in case of autism spectrum disorders and/or
for hyperactivity and attention disorders [52]. This obser-
vation raises the question of the use of methylphenidate in
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those cases (for its effect on hyperactivity and as a wake-
promoting agent in patients with comorbid sleep disturb-
ance [29, 53, 54]. Anxiety and major depressive disorders
can also be observed. It is to note that aggressiveness is
not strongly linked to the presence of autism features or
of hyperactivity. It seems mainly correlated to attention
disorders but that does not mean a causal effect between
these two features [50].
Behavior and sleep disorders
Maladaptive behaviors are often exacerbated by irregular
sleeping patterns. Sleep disorders are common in neuro-
developmental disorders. For example 32 % of patients
with fragile X syndrome had at least one indication of
abnormal sleep in a parental survey study [55]. Sleep dis-
orders are also frequent in many other disorders such as
Rett or Prader Willi syndrome for example. Studies do
not always concur on the nature of sleep disturbances in
these syndromes which are usually multi-factorial [56].
Sleep disorder in SMS syndrome are a particular case
among neurodevelopmental disorders and therapeutic
strategies follow those particularities. First, sleep/wake
disorders are almost constant in the syndrome. They are
intense with heavy consequences on the caregivers. Sec-
ond, the link between SMS sleeps disorders and inverted
melatonin secretion is clearly established. As underlined
by Ann Smith, in the 7 th international American con-
ference on Smith Magenis syndrome: when untreated,
‘sleep disorders are the biggest problem in SMS’. Diurnal
secretion of melatonin is associated with ‘jet lag-like’
drowsiness and therefore plays a major role in daytime
behavioral disorders, especially among the youngest
individuals. This aspect is usually alleviated by the use of
beta-blockers. Conversely, the absence of nocturnal
melatonin is a causal factor of shortened, fragmented
nighttime sleep [30, 57] supporting as well behavioral
disorders. Actually sleep deprivation, even in healthy
children, contribute to neurocognitive disorders and
disruptive behaviors. For example it may increase hyper-
activity and attentional disorders. Sleep deprivation
interfere with memory consolidation -especially semantic
memory- and increase anxiety [55, 58, 59]. Nevertheless, in
SMS residual maladaptive behavior often persists despite
the treatment of sleep disturbances, and tends to increase
with age. Thus, restlessness and aggressiveness (directed at
oneself and/or others) seem inherent to SMS syndrome.
Fig. 2 Proposal of a multimodal management of the behavioral disorders in SMS. Treatment of SMS is complex and includes: geneticists,
neuropediatricians/neurologists, somnologists, developmental and behavioral pediatricians, psychiatrists, speech and language therapists,
neuropsychologists, psychomotor therapists
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Behavior and pain
Decreased sensitivity to pain is a common feature of
SMS [20, 37]. However, its precise pathophysiology re-
mains unknown. This phenomenon is generally considered
as a reflection of an underlying peripheral neuropathy
linked to the loss of the PMP22 gene across the microdele-
tion. On the other hand, one functional MRI and H2O
PET study suggests the involvement of the central nervous
system, and more precisely of the insular cortex [37]. The
contribution of this decreased sensitivity to pain to behav-
ioral disturbances remains to be defined. As underlined by
Boddaert et al., pathological conditions with reduced sensi-
tivity to pain are not necessarily associated with self-injury
[37]. On the other hand, a high threshold of pain may hide
medical conditions, such as dental infection, that may
support behavioral disturbances.
Behavior and neurocognition
Behavioral disorders are partly related to neurocognitive
impairment. Speech delay especially may lead to intense
temper tantrums. Difficulties understanding prohibitions
and implicit notions may lead to maladaptive behavior.
Similarly, sexual development during adolescence may
be associated with specific behavioral disorders that re-
quire further studies.
Behavior and environment
The patient’s environment has a significant impact on
behavior. An astute study by Taylor and al., suggests that
SMS self-injurious behavior and aggressive/disruptive
outbursts are often evoked by low levels of adult atten-
tion and lead to increased levels of attention following
the behaviors [51]. In our experience, this kind of be-
havior is exacerbated when the children are interacting
with their close relatives, especially their mother.
On the other hand, emotional impact of having a child
with SMS and behavioral problems may in turn in-
creases the disorders. It is noteworthy that one of the
characteristics of the SMS is that sleep disorders are so
deep that the family is usually exhausted which deepens
the difficulty to face the behavioral disruptive disorders.
Suffering at school or in the institution may emerge
from conflicts with other persons (students or teaching
staff ) or poor school performance. All those situations
should be systematically identified and evaluated.
In adulthood, the complete clinical picture entails
poor social adjustment, often ending in institutionali-
zation, with symptoms tending to resist or escape
treatment [29, 45].
Treatment strategies to prevent behavioral
disturbance
So far, as for many orphan diseases, no general consen-
sus on the treatment of behavioral disorders in SMS has
been reached, and there are no recommendations on the
prescription of psychotropic drugs [54]. However, an
optimal strategy should integrate all the parameters
detailed in Fig. 2.
Psychiatric symptoms should be precisely identified to
determine case-specific medication. The antipsychotic
monotherapy is indicated in order to limit side effects.
The use of clozapine seems of particular interest in
SMS. If required, antipsychotic cotreatment may be
superior to monotherapy.
The use of methylphenidate for hyperactivity may also
require further evaluation, especially during adulthood.
Nevertheless, behavior management is not limited to
medication and treatment should be comprehensive and
integrative.
Behavior and sleep disorders
Because sleep disorders favors behavioral disturbances
that may in turn increase sleep disruptive behavior, they
should be treated as soon as they appear. For this rea-
son, an annual evaluation seems of interest in SMS. The
treatment has been proposed on the basis of the known
inversion of melatonin secretion in SMS [30, 31]. Usual
medication includes melatonin in the evening (in general,
2 to 6 mg of prolonged-release melatonin) and beta-
blockers (such as Acebutolol, 10 mg/kg) in the morn-
ing [60]. No clinical trial testing the effectiveness of
the various pharmacological regimens proposed for
treatment has been published so far. Education of the
parents is an important component for the regulation
of sleep disorders (e.g. avoiding sleeping with the
child, no invasive games or rituals during night wakings,
etc.…). The exact frequency of sleep breathing disorders is
unknown in SMS. The risk is probably higher than in the
general population, especially because of frequent over-
weight/obesity and use of high posology of antipsychotic
medication [2, 19–21]. Sleep breathing disorders should
be evocated in case of daytime sleepiness resisting to beta
blockers, especially in patients with android obesity and/
or taking psychotropic drugs. In our experience, sleep dis-
orders spontaneously improve in young adults but the rea-
sons remain unclear. Thus, whenever possible, treatment
interruption should be considered to assess the usefulness
of continuing pharmacological intervention.
Behavior and pain
When facing a recent increase of behavioral disorders, the
practitioner should consider the possibility of an under-
lying medical condition. Optimal intervention requires the
systematic research and treatment of pain, including
inflammatory, dental, acute, chronic, premenstrual, visceral
pain and headaches. In our experience, a dramatic increase
of aggressive and/or self-injurious behaviors may only
reveal severe transit disorders in SMS adults.
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Behavior and neurocognition
In general, language and speech therapies are a major
stake in the early prevention of behavioral disorders,
especially in case of language delay. In SMS, it should be
initiated as soon as possible (by the age of 6–8 months)
as a priority, using signs and symbols such as pictograms
or the MAKATON method. A multimodal approach to
communication is recommended because the main diffi-
culties concern the expressive language [61, 62]. Language
therapy is designed to help children gain access to oral
language and limit the frustration due to their poor ability
to express themselves. It relies among others on self-
expression activities, and swallowing and tongue position-
ing exercises. Augmentative communication approaches
are standard for children with severe expressive language
delay/impairment. They may include eye tracking devices
for children with special needs such as motor impairment.
Its interest in SMS children, especially those with autism
spectrum disorders and/or hyperactivity, requests further
studies [63, 64]. Dyspraxia may require psychomotor
therapy.
Neuropsychological assessment is useful in drawing up
the overall picture of the child's skills. Knowing the full
extent of their capacities is important since it helps the
children improve their practice; it also enables practi-
tioners to adapt the treatment to the child (e.g. with the
use of a computer) and propose appropriate schooling.
Activities requiring the use of visuospatial, sequential
and coordination skills are also recommended. In associ-
ation with pharmacological approaches, cognitive remedi-
ation is of peculiar interest in SMS. SMS cognitive profile
is often heterogeneous with relatively preserved skills
alongside specific deficits. Remediation helps develop
adapted strategies to supply for impaired cognitive
processes, which is paramount in developing the pa-
tient’s autonomy. Last but not least, deficits such as
attention deficit or hyperactivity may induce conduct
disorders [62, 65–67]. Thus, cognitive remediation
may have a positive impact on SMS behavioral disor-
ders and reduce the number of institutionalized SMS
patients in the long term.
Behavior and environment
At school, SMS children are easily distracted and hyper-
active. Hence, small classes are more adapted because
they offer a more structured, less distracting learning
environment. Working with the teaching staff (especially
specialized personnel) is of utmost importance. Because
SMS children have difficulty adapting to change (due to
low cognitive flexibility), they have to be warned and
prepared in order to avoid anxiety-related manifestations
of their behavioral problems. Children should develop
in the most stable possible school environment – one
that enhances their sense of security. Given that these
children have trouble understanding sequential infor-
mation, the use of a pictorial calendar and timer may
help them form concrete mental images of passing
time and daily schedule. SMS adolescents and young
adults should be encouraged to achieve autonomy.
Their academic and then occupational careers should
be adapted to their competencies and guided by their
results on recent neuropsychological assessments. An-
other key part of the treatment involves working with
the family and providing parental guidance.
Given the fascination of SMS children for screens the
use of computers and pads may be useful to reinforce
their learnings. For fine motors skills example writing
with a pen is harder in SMS because of fine motors skill
disabilities and reading is also hard because of atten-
tional disorders. Using a pad or a computer may help
SMS of all ages to start to read and write.
Last but not least, regular psychiatric follow-up is
paramount in the management of these patients In SMS,
clinical practice suggests a benefit of interventions focus-
ing on providing parent training and cognitive behavioral
therapy (CBT). Bolstering social skills and managing
challenging behaviors or sleep disturbances may improve
social communication, language use, and potentially
symptom severity. But the lack of consistent data limits
our understanding of whether these interventions are
linked to specific clinically meaningful changes in SMS
functioning. Stress, anxiety and mood disorders are associ-
ated with faulty emotional regulation. A large proportion
of persons with intellectual disabilities show these symp-
toms [68]. Aggression and physical violence could be
enhanced by a poor control in emotional regulation [69].
This situation might explain the particularly high
prevalence of challenging behavior in SMS people.
For Whitaker, there seems to be some evidence that
cognitively based emotions control treatment can be
effective with people who have learning disabilities
[70]. Mindfulness-Based Treatment has been adapted
in Individuals with mild intellectual disabilities and
physical and verbal aggression behaviors [71]. Its precise
interest in SMS remains to be evaluated.
All these measures are not limited to children and
should be carried on throughout the life of the patient.
Summary
The prognosis of SMS patients today is closely linked
to their behavioral manifestations. In adulthood, they
sometimes require repeated hospitalizations in psychi-
atric wards, or may even have to be institutionalized.
Treatment of SMS is complex and requires a multidiscip-
linary team including, among others, geneticists, neurope-
diatricians/neurologists, somnologists, developmental and
behavioral pediatricians, psychiatrists and speech and lan-
guage therapists. An optimal care plan includes treating
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sleep/wake rhythm disturbances and behavioral disorders.
Another key part of the treatment involves working with
the family and providing parental guidance. In any case,
the emphasis should be on valorizing each individual's
abilities in order to help them overcome their specific
difficulties. Lastly, the issue of treating behavioral disor-
ders related to syndromes is not limited to SMS, and the
propositions developed in this paper extend to the large
group of genetic disorders associated with neurobeha-
vioral phenotypes.
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